Case Discussions on Optimal Integration of Checkpoint Inhibitors Into the Management of Stage III NSCLC

Download this slideset to gain insights from our multidisciplinary panel of experts on the optimal use of concurrent chemoradiation and checkpoint inhibition in the treatment of a series of case patients with stage III NSCLC.
Gerard A. Silvestri, MD, MS
Program Director
Kristin Higgins, MD
Mark A. Socinski, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 3.87 MB
Released: October 21, 2019


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by an educational grant from

Related Content

From Clinical Care Options, Zofia Piotrowska, MD, MHS, and Stephen V. Liu, MD, review key data from studies of lung cancer treatment presented at ASCO 2020

Stephen V. Liu, MD Zofia Piotrowska, MD, MHS Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: September 25, 2020 Expired: September 24, 2021

Gain key clinical insights fast, with this short slideset from CCO on lung cancer data presented at 2020 ASCO

Stephen V. Liu, MD Zofia Piotrowska, MD, MHS Released: September 25, 2020

Gain key clinical insights fast with this short slideset from CCO on RET fusion–positive NSCLC

Dara L. Aisner, MD, PhD Joshua Bauml, MD Released: September 17, 2020

Gain key expert insights fast with this short slideset from CCO on biomarkers critical to optimal use of targeted therapy and immunotherapy for NSCLC

Matthew Gubens, MD, MS Sanjay Mukhopadhyay, MD Released: September 11, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.